CDR-404 by CDR-Life for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

CDR-404 is under clinical development by CDR-Life and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

Amylyx ventures into metabolic diseases market with $35.1m deal – Pharmaceutical Technology

On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental glucagon-like peptide-1 (GLP-1) receptor antagonist, avexitide, for $35.1m. Avexitide was previously developed for post-bariatric

June 28, 2024

Ancillary Cannabis Stocks Hold Prices the Best

As we described in an article released earlier, the Global Cannabis Stock Index moved lower in November, falling 9.5%. It is now down 8.3% in 2024. In this

November 30, 2024

Research sheds light on continuous development of social understanding from adolescence into early adulthood

The capability to reflect on their own mental state and that of others continues to develop throughout adolescence, with mentalizing scores varying by gender and

June 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.